About the Company
xeris aspires to break through this restraint by developing ultra-low volume, ready-to-use biotherapeutics delivered through patient-friendly injectable devices. products built on our xeriject technologies could potentially ease the pain of injections for hundreds of millions of patients.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $XERS News
Here's What Analysts Are Forecasting For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) After Its Annual Results
There's been a major selloff in Xeris Biopharma Holdings, Inc. ( NASDAQ:XERS ) shares in the week since it released ...
Xeris Biopharma Holdings Inc (XERS) Reports Robust Revenue Growth in Q4 and Full Year 2023
Guidance for 2024: Projects total net revenue of $170M-$200M and year-end cash position of $55M-$75M.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2023 Earnings Call Transcript
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2023 Earnings Call Transcript March 6, 2024 Xeris Biopharma Holdings, Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the ...
Xeris Biopharma Holdings Inc
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Xeris Biopharma Holdings Inc (XERS): A Fresh Data-Based Analysis
If we refocus on Xeris Biopharma Holdings Inc (NASDAQ:XERS), historical trading data shows that trading volumes averaged 2.21 million over the past 10 days and 2.15 million over the past 3 months. The ...
Why Xeris (XERS) Might Surprise This Earnings Season
Investors are always looking for stocks that are poised to beat at earnings season and Xeris Biopharma Holdings, Inc. XERS may be one such company. The firm has earnings coming up pretty soon, and ...
Xeris Biopharma: Q4 Earnings Snapshot
CHICAGO — CHICAGO — Xeris Biopharma Holdings, Inc. (XERS) on Wednesday reported a loss of $13.4 million in its fourth quarter. The Chicago-based company said it had a loss of 10 cents per share. Get a ...
Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing ...
Xeris Biopharma: Q4 Earnings Snapshot
CHICAGO (AP) — CHICAGO (AP) — Xeris Biopharma Holdings, Inc. (XERS) on Wednesday reported a loss of $13.4 million in its fourth quarter. The Chicago-based company said it had a loss of 10 ...
Loading the latest forecasts...